Which Preventive Health Screenings Do You Actually Need?

Ask five different sources what preventive screenings you actually need and you'll likely get five different answers — one from your GP, one from your insurer's coverage list, one from a wellness account online, and a couple more depending on which country's guidelines you happen upon. The confusion is real. The underlying evidence, fortunately, is not nearly as murky as the noise around it suggests.

What the evidence-graded guidelines actually recommend

The U.S. Preventive Services Task Force (USPSTF) publishes the most rigorously evidence-graded screening recommendations available, and its independent panel assigns each one a letter grade based on the strength of evidence for benefit versus harm. "A" and "B" grades — meaning the evidence supports a substantial or moderate net benefit — form the backbone of most Western preventive care guidance. As of 2026, current A/B recommendations for adults include:

• Blood pressure — screening for all adults 18 and older (Grade A, April 2021)
• Colorectal cancer — screening from age 45–49 (Grade B) and 50–75 (Grade A), May 2021
• Breast cancer — biennial mammography for women 40–74 (Grade B), April 2024
• Cervical cancer — cytology every 3 years from age 21, or HPV-based testing every 5 years from 30–65 (Grade A, August 2018)
• Lung cancer — annual low-dose CT for adults 50–80 with a 20 pack-year smoking history (Grade B, March 2021)
• Prediabetes and type 2 diabetes — screening for adults 35–70 with overweight or obesity (Grade B, August 2021)
• Statin therapy — for adults 40–75 with at least one cardiovascular risk factor and an estimated 10-year CVD risk of 10% or higher (Grade B, August 2022)
• Osteoporosis — screening for women 65 and older (Grade B, January 2025), or younger postmenopausal women with specific risk factors
• Hepatitis C — one-time screening for adults 18–79 (Grade B, March 2020)
• Abdominal aortic aneurysm — one-time ultrasound for men 65–75 who have ever smoked (Grade B, December 2019)

These aren't arbitrary. Each one reflects the Task Force weighing population-level evidence for benefit against the evidence for harm and cost of over-testing — which is exactly why the list is shorter than most people expect.

What this looks like in Switzerland

Switzerland doesn't run screening through a single national body. Cancer screening in particular is organised cantonally, and the exact offer varies by where you live. As of 2025, 11 of the cantonal colorectal cancer screening programmes studied invite residents aged 50 to 69 to screen using a fecal immunochemical test (FIT) every two years, or a colonoscopy every ten years, with the Federal Office of Public Health (FOPH) ensuring both are covered under compulsory insurance without the usual deductible. Where organised mammography programmes exist, they generally invite women aged 50 to 69 for a mammogram every two years; cervical cytology is covered by compulsory insurance every three years for women 21–70, following two initial annual tests. Coverage and invitation systems both vary by canton — worth confirming directly with your cantonal cancer league if you're unsure which programme applies to you.

Where the guidelines stop

Grade A and B recommendations are built for population-level screening: catching the highest-burden, most common conditions in people with no symptoms, at the lowest cost and lowest risk of over-testing. That is a genuinely useful bar to clear — and it is, by design, a floor rather than a ceiling.

None of the above tells you whether your ApoB is elevated relative to your LDL, a stronger predictor of cardiovascular risk for many people than a standard lipid panel alone. None of it screens for Lp(a), a largely genetic risk factor carried by roughly 1 in 5 people that current guidelines don't recommend testing routinely, despite its strength as a predictor of premature cardiovascular disease. None of it looks at fasting insulin, which can flag insulin resistance years before fasting glucose crosses a diagnostic threshold. And none of it is personalised beyond age and a small number of standard risk factors.

This is where a comprehensive biomarker panel earns its place — not as a replacement for the screenings above, which remain the evidence-backed foundation, but as the layer on top of them for anyone who wants a fuller picture of their own biology than the population minimum provides.

How Aeonix fits in

Aeonix panels run alongside your existing screenings, not instead of them. Our four tiers span up to 150+ individually billed biomarkers across cardiovascular, metabolic, hormonal, inflammatory, and oncological domains, reviewed by a qualified physician and returned within 48 hours. The goal isn't to replace your GP or your cantonal screening invitation — it's to close the gap between what population guidelines require and what your own biology can actually tell you.